D/E 0.54 — below the Consumer Defensive debt median (≈40th pctile)
P/E19.1xB
P/E 19.1 — near the Consumer Defensive median (≈60th pctile)
PEG0.88B+
PEG 0.88 — near fair value, classic Lynch benchmark (1.0)
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 81.4
Quality0.80
Growth0.90
Value0.75
Why this score
Buying back stock
Entry · Margin of safety
52-week rangeMid-range
16% off the 12-month high
vs DCF fair value47% belowest. fair value ~$246
Quality signals · context only
Gross profitability40% · B+gross profit ÷ total assets (Novy-Marx)
ROIC15.5% · A-return on invested capital — not score-weighted
Why now
Covista Inc. is a compelling growth story, uniquely positioned in the high-demand healthcare education sector, evidenced by its robust 12.9% FY YoY revenue growth. Its strong operational efficiency delivers a healthy 12.3% profit margin, while a 0.88 PEG ratio suggests the market is underpricing this growth relative to earnings. The crux of the thesis rests on the persistent, inelastic demand for skilled professionals in nursing, medical, and veterinary fields, which Covista's Chamberlain and American University of the Caribbean programs are purpose-built to address.
Moat
Covista's durable edge stems from its established accreditation and specialized curriculum across its Chamberlain, Walden, and Medical and Veterinary segments, particularly in high-barrier-to-entry fields like nursing and medical postsecondary education. The company's extensive program offerings, from bachelor's to doctoral degrees and online certificates, create significant switching costs for students seeking comprehensive and recognized qualifications. This breadth and depth, combined with a 17.2% ROE, make it difficult for new entrants to quickly replicate Covista's integrated educational ecosystem and reputation.
Risk
The primary bear case against Covista centers on potential regulatory shifts within the education sector, particularly concerning federal funding or accreditation standards, which could disproportionately impact its multi-segment operations across the US and Caribbean. While its debt-to-equity of 0.54 is manageable, any significant slowdown in enrollment growth or increased competition in online learning could pressure its $336m TTM FCF generation. The concrete signal confirming the bear case would be a sustained decline in new student enrollments across its core healthcare programs, leading to a contraction in profit margins.
Horizon
1-3 yr $156.25 (4-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $197.26 at ~8% CAGR — dividend + buyback compounding. 10 yr $252.98 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · CVSA
$
%
%
Shares to buy
15
Position size
$1,970
3.9% of portfolio
Stop price
$98.49
25% below $131.32
$ at risk if stopped
$492.45
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Covista Inc. (CVSA): score, valuation & FAQ
Covista Inc. (CVSA) is a Education & Training Services company that scores 81.4 out of 100 on the Bull Rankings quality-growth model — a strong reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (B+), D/E (B+) and PEG (B+). On valuation, CVSA sits about 47% below our discounted-cash-flow fair value (a margin of safety).
Is CVSA a good stock to buy?
Bull Rankings scores CVSA 81.4 out of 100 on its quality-growth model, which is a strong reading. That is driven by Rev (B+), D/E (B+) and PEG (B+). A score is a quantitative screen of Covista Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does CVSA score 81.4 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). CVSA earns its highest marks on Rev (B+), D/E (B+) and PEG (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is CVSA overvalued or undervalued?
Based on $131.32, CVSA sits about 47% below our discounted-cash-flow fair value (a margin of safety). It trades at a 19.1x× P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in CVSA?
The primary bear case against Covista centers on potential regulatory shifts within the education sector, particularly concerning federal funding or accreditation standards, which could disproportionately impact its multi-segment operations across the US and Caribbean. While its debt-to-equity of 0.54 is manageable, any significant slowdown in enrollment growth or increased competition in online learning could pressure its $336m TTM FCF generation. The concrete signal confirming the bear case would be a sustained decline in new student enrollments across its core healthcare programs, leading to a contraction in profit margins.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.